التفاصيل البيبلوغرافية
| العنوان: |
Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity |
| المؤلفون: |
Hsu, Yi-Chiung, Chen, Hsuan-Yu, Yuan, Shinsheng, Yu, Sung-Liang, Lin, Chia-Hung, Wu, Guani, Yang, Pan-Chyr, Li, Ker-Chau |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2013 |
| المجموعة: |
BioMed Central |
| مصطلحات موضوعية: |
NCI-60, Invasion, Metastasis, Microarray, Chemotherapy |
| الوصف: |
Background Chemosensitivity and tumor metastasis are two primary issues in cancer management. Cancer cells often exhibit a wide range of sensitivity to anti-cancer compounds. To gain insight on the genetic mechanism of drug sensitivity, one powerful approach is to employ the panel of 60 human cancer cell lines developed by the National Cancer Institute (NCI). Cancer cells also show a broad range of invasion ability. However, a genome-wide portrait on the contributing molecular factors to invasion heterogeneity is lacking. Methods Our lab performed an invasion assay on the NCI-60 panel. We identified invasion-associated (IA) genes by correlating our invasion profiling data with the Affymetrix gene expression data on NCI-60. We then employed the recently released chemosensitivity data of 99 anti-cancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, we collected data from four independent drug-testing experiments to validate our findings on compound response prediction. Finally, we obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of our gene signature for patient outcome prediction. Results First, we found 633 IA genes from the invasion-gene expression correlation study. Then, for each of the 99 drugs, we obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. We identified a set of eight genes ( EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT ) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib. This eight-gene signature (derived from NCI-60) for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel. The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients (log-rank P = 0.0263; 0.00021). Multivariate ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
http://www.biomedcentral.com/1741-7015/11/106Test |
| الإتاحة: |
http://www.biomedcentral.com/1741-7015/11/106Test |
| حقوق: |
Copyright 2013 Hsu et al.; licensee BioMed Central Ltd. |
| رقم الانضمام: |
edsbas.4AB4829C |
| قاعدة البيانات: |
BASE |
